Jeffrey Crawford | Duke Department of ...

Dr. Jeffrey Crawford

Claim this profile

Duke University Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
21 reported clinical trials
57 drugs studied

About Jeffrey Crawford

Education:

  • Obtained an MD from the University of North Carolina School of Medicine in 1978.
  • Completed a Residency in Internal Medicine at Duke University Medical Center in 1981.
  • Finished a Fellowship in Hematology/Oncology at Duke University Medical Center in 1983.

Experience:

  • Currently a Professor of Medicine at Duke University School of Medicine.
  • Serves as the Director of the Breast Cancer Program at the Duke Cancer Institute.

Area of expertise

1

Lung Cancer

Jeffrey Crawford has run 8 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage I
2

Non-Small Cell Lung Cancer

Jeffrey Crawford has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage I

Affiliated Hospitals

Image of trial facility.

Duke University Medical Center

Image of trial facility.

Duke Raleigh Hospital

Clinical Trials Jeffrey Crawford is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Perioperative Chemotherapy

for Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Recruiting

4 awards

Phase 3

18 criteria

More about Jeffrey Crawford

Clinical Trial Related

7 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Jeffrey Crawford has experience with

  • Pembrolizumab
  • Carboplatin
  • Autologous Hematopoietic Stem Cell Transplantation
  • Rituximab
  • Paclitaxel
  • Pemetrexed Disodium

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jeffrey Crawford specialize in?

Is Jeffrey Crawford currently recruiting for clinical trials?

Are there any treatments that Jeffrey Crawford has studied deeply?

What is the best way to schedule an appointment with Jeffrey Crawford?

What is the office address of Jeffrey Crawford?

Is there any support for travel costs?